MNKD vs SLN: stock comparison and AI forecast
Mannkind Corp (MNKD) and Silence Therapeutics Plc (SLN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MNKD Mannkind Corp
- Market Cap
- $1.17B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
SLN Silence Therapeutics Plc
- Market Cap
- $1.19B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MNKD and SLN have similar market capitalizations ($1.17B and $1.19B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MNKD | SLN |
|---|---|---|
| Market Cap | $1.17B | $1.19B |
| P/B Ratio | – | 30.93x |
| EPS | $-0.04 | $-0.53 |
| Book Value/Share | – | $0.64 |
| Revenue/Share | $1.22 | $0.01 |
| FCF/Share | $-0.06 | $-0.70 |
Profitability & Margins
| Metric | MNKD | SLN |
|---|---|---|
| ROIC | 1.6% | -72.9% |
| Gross Margin | 89.8% | 69.8% |
| Operating Margin | 2.3% | -9023.4% |
| EBT Margin | -12.4% | -7919.6% |
| Tax Rate | 10.4% | 0.0% |
Financial Health
| Metric | MNKD | SLN |
|---|---|---|
| Current Ratio | 1.72x | 7.42x |
| Quick Ratio | 1.41x | – |
| D/E Ratio | – | 1.77x |
| Financial Leverage | – | 2.77x |
| Working Capital | $103M | $82M |
Cash Flow
| Metric | MNKD | SLN |
|---|---|---|
| Operating Cash Flow | -$8M | -$42M |
| Free Cash Flow | -$18M | -$42M |
| Capital Spending | -$10M | $0.00M |
| OCF Growth YoY | -123.3% | – |
| FCF Growth YoY | -163.0% | – |
| FCF/Sales | -4.6% | -5583.4% |
| CapEx/Sales | 2.6% | 0.4% |
Operational Efficiency
| Metric | MNKD | SLN |
|---|---|---|
| Asset Turnover | 0.54x | 0.01x |
| Receivables Turnover | 9.1x | – |
| Inventory Turnover | 0.9x | – |
| Fixed Assets Turnover | 4.6x | 0.6x |
| Days Sales Outstanding | 40 days | – |
| Days Inventory | 402 days | – |
| Payables Period | 100 days | – |
| Cash Conversion Cycle | 342 days | – |
Income Statement
| Metric | MNKD | SLN |
|---|---|---|
| Total Revenue | $394M | $760K |
| Operating Income | $9M | -$68M |
| R&D Expense | $77M | $48M |
| SG&A Expense | $200M | – |
| Cost of Goods Sold | $40M | $90K |
Dividend & Shareholder Information
| Metric | MNKD | SLN |
|---|---|---|
| Shares Outstanding | 322M | 60M |
| EPS Growth | -136.4% | – |
MNKD vs SLN: stock comparison and AI forecast
Which is bigger, MNKD or SLN?
MNKD and SLN have similar market capitalizations ($1.17B and $1.19B).
Which one does Intratio's AI model rank higher, MNKD or SLN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.